Powered by OpenAIRE graph
Found an issue? Give us feedback

Phase III multicenter trial comparing imatinib 400mg versus imatinib 600mg versus imatinib 400 mg plus cytarabine versus imatinib 400 mg combine with pegylated Interferona2a for the treatment of patients with chronic myeloid leukaemia in chronic phase-SPIRIT Ancillary study A pharmacogenetic study of response and tolerance to imatinib alone or in combination in patients treated for de novo chronic phase CML.

Funder: Institut National du CancerProject code: INCa-DGOS-3706 Call for proposal: PHRC11
Funded under: PHRC

Phase III multicenter trial comparing imatinib 400mg versus imatinib 600mg versus imatinib 400 mg plus cytarabine versus imatinib 400 mg combine with pegylated Interferona2a for the treatment of patients with chronic myeloid leukaemia in chronic phase-SPIRIT Ancillary study A pharmacogenetic study of response and tolerance to imatinib alone or in combination in patients treated for de novo chronic phase CML.

Powered by OpenAIRE graph
Found an issue? Give us feedback

Do the share buttons not appear? Please make sure, any blocking addon is disabled, and then reload the page.

All Research products
arrow_drop_down
<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=inca________::d657443761e90f06a91ceaa17b04f75d&type=result"></script>');
-->
</script>
For further information contact us at helpdesk@openaire.eu

No option selected
arrow_drop_down